NOVEMBER
Incorporated in Delaware under the name Advanced Medicine, Inc.
APRIL
Changed its name to Theravance, Inc.
NOVEMBER
Innoviva / GSK collaboration agreement signed
OCTOBER
Breo launched in the US
APRIL
Anoro launched in the US
JUNE
Spun-off research and development operations
JANUARY
Rebranded to Innoviva, Inc.
OCTOBER
Trelegy launched in the US.
JANUARY
Armata* and Innoviva announced strategic investment
JUNE
Entasis and Innoviva announced private placement
MAY
Innoviva announced strategic repurchase of GSK’s equity stake
MAY
Announced acquisition of Entasis Therapeutics
JULY
Announced acquisition of La Jolla Pharmaceutical Company
JULY
Sold 15% stake in Theravance Respiratory Company**
MAY
Announced integration of Entasis and La Jolla into Innoviva Specialty Therapeutics
MAY
FDA approval of XACDURO®
NOVEMBER
Announced successful zoliflodacin Phase III results in uncomplicated gonorrhea
DECEMBER
Announced acquisition of U.S. commercial rights for ZEVTERA®
JULY
ZEVTERA® launched in the U.S.
OCTOBER
XACDURO® and ZEVTERA® nominated for 2025 Prix Galien USA Award
DECEMBER
FDA approval of NUZOLVENCE®
